---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-006866"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:20:59.092040+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dogwood Therapeutics Q1 2025 net loss $12.2M; Halneuron Phase 2b dosing underway

## Summary
- Net loss of $12.2M ($8.45 per share) vs $1.3M ($1.68) in Q1 2024; R&D spend rose to $2.4M.
- Halneuron Phase 2b CINP study initiated; interim data readout expected Q4 2025.
- $19.5M loan from CK Life Sciences affiliate converted to equity; $4.8M gross common stock raise.
- Cash and equivalents of $17.5M provides operational runway through Q1 2026.
- Regained Nasdaq compliance with minimum stockholders' equity of $2.5M.

## SEC filing metadata
- accession: 0001558370-25-006866
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837025006866/0001558370-25-006866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837025006866/dwtx-20250508x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-006866
- JSON: https://secwatch.observer/filing/0001558370-25-006866.json
- Plain text: https://secwatch.observer/filing/0001558370-25-006866.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.